Skip to main content

Table 1 Study participant characteristics at enrollment

From: MiR-1231 decrease the risk of cancer-related mortality in patients combined with non-small cell lung cancer and diabetes mellitus

Variation

Total (n = 108)

Cohort, median (IQR)

P value

miR-1231 < 1.775

miR-1231 ≥ 1.775

Age (year)

64.08 ± 7.6

64.69 ± 7.76

63.48 ± 7.47

0.413

BMI (kg/m2)

23.9 ± 3.53

23.82 ± 3.75

23.98 ± 3.33

0.819

Serum CEA level (ng/mL)

3.9 (1.83, 13.43)

5.92 (2.41, 38.39)

3.12 (1.47, 6.91)

0.021*

Serum CRP level (μmol/L)

9.49 (2.38, 13.34)

11 (4.26, 13.28)

5.99 (2.14, 13.37)

0.227

Albumin level (g/L)

40.01 ± 5.21

39.46 ± 4.83

40.57 ± 5.56

0.272

Neutrophils count (109/L)

4.68 (3.53, 6.27)

4.72 (3.67, 6.08)

4.68 (3.37, 6.4)

0.549

Lymphocytes count (109/L)

1.68 (1.23, 2.15)

1.47 (1.18, 2.02)

1.75 (1.36, 2.3)

0.073

Hemoglobin level (g/L)

133 (123, 142.25)

133.5 (123.25, 144.75)

131.5 (123, 141.75)

0.412

Platelet count (109/L)

228.5 (186, 289)

225.5 (183.25, 291)

243.5 (200.25, 283.25)

0.365

PNI score

49.22 (44.03, 53.94)

47.62 (43.12, 51.64)

50.05 (44.48, 55.7)

0.101

NLR

2.9 (2.01, 4.49)

3.19 (2.37, 4.66)

2.69 (1.86, 3.87)

0.098

Gender (n %)

   

0.534

 Female

34 (31)

15 (28)

19 (35)

 

 Male

74 (69)

39 (72)

35 (65)

 

Pathologic type (n %)

   

0.547

 Adenocarcinoma

58 (54)

29 (54)

29 (54)

 

 Mixed lung cancer

17 (16)

7 (13)

10 (19)

 

 Large cell lung cancer

5 (5)

4 (7)

1 (2)

 

 Squamous carcinoma

27 (25)

14 (26)

13 (24)

 

 Others

1 (1)

0 (0)

1 (2)

 

Metastasis, n (%)

   

0.177

 No

50 (46)

21 (39)

29 (54)

 

 Yes

58 (54)

33 (61)

25 (46)

 

Stage of NSCLC

   

0.005**

 Stage I

17 (16)

4 (7)

13 (24)

 

 Stage II

8 (7)

6 (11)

2 (4)

 

 Stage III

20 (19)

6 (11)

14 (26)

 

 Stage IV

63 (58)

38 (70)

25 (46)

 

Surgery (n %)

   

0.001**

 No

66 (61)

42 (78)

24 (44)

 

 Yes

42 (39)

12 (22)

30 (56)

 

Therapy of radiation (n %)

   

0.238

 No

65 (60)

29 (54)

36 (67)

 

 Yes

43 (40)

25 (46)

18 (33)

 

Application of platinum (n %)

   

1

 No

3 (3)

2 (4)

1 (2)

 

 Yes

105 (97)

52 (96)

53 (98)

 

Chemotherapy

   

0.573

 AP

45 (42)

25 (46)

20 (37)

 

 DP

13 (12)

6 (11)

7 (13)

 

 EP

14 (13)

8 (15)

6 (11)

 

 GP

8 (7)

2 (4)

6 (11)

 

 Others

28 (26)

13 (24)

15 (28)

 

Target therapy (n %)

   

0.02*

 No

76 (70)

32 (59)

44 (81)

 

 Yes

32 (30)

22 (41)

10 (19)

 

Application of TKI (n %)

   

0.006**

 No

82 (76)

34 (63)

48 (89)

 

 TKI I

19 (18)

15 (28)

4 (7)

0.006**

 TKI III

7 (6)

5 (9)

2 (4)

 

Application of VEGF inhibitor, n (%)

   

0.775

 No

94 (87)

48 (89)

46 (85)

 

 Yes

14 (13)

6 (11)

8 (15)

 

KPS score, n (%)

   

0.013*

 20

1 (1)

0 (0)

1 (2)

 

 50

3 (3)

2 (4)

1 (2)

 

 60

1 (1)

1 (2)

0 (0)

 

 70

9 (8)

6 (11)

3 (6)

 

 80

31 (29)

22 (41)

9 (17)

 

 90

40 (37)

16 (30)

24 (44)

 

 100

23 (21)

7 (13)

16 (30)

 

Smoking, n (%)

   

1

 No

51 (47)

26 (48)

25 (46)

 

 Yes

57 (53)

28 (52)

29 (54)

 

Hypertension, n (%)

   

1

 No

39 (36)

20 (37)

19 (35)

 

 Yes

69 (64)

34 (63)

35 (65)

 

Hyperlipemia, n (%)

   

0.215

 No

88 (81)

41 (76)

47 (87)

 

 Yes

20 (19)

13 (24)

7 (13)

 

Heart failure, n (%)

   

0.495

 No

106 (98)

52 (96)

54 (100)

 

 Yes

2 (2)

2 (4)

0 (0)

 

ACS, n (%)

   

1

 No

105 (97)

52 (96)

53 (98)

 

 Yes

3 (3)

2 (4)

1 (2)

 
  1. IQR, interquartile range; CRP, C-reactive protein; PNI, neutrophil lymphocyte ratio; NLR, neutrophil lymphocyte ratio; NSCLC, non-small-cell lung cancer; TKI, Tyrosine Kinase Inhibitor; VEGF, vascular endothelial growth factor; KPS, Karnofsky Performance Status; ACS, acute coronary syndrome. ***P < 0.001, **P < 0.01, *P < 0.05